StreetInsider.com News Articles

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company’s global workforce, inclusive of employees engaged through employer-of-record (EOR) arrangements. Anticipated annualized savings as a result of this action are expected to be approximately $13.6 million.

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Mon, 22 Sep 2025 16:30:00 -0500

This workforce reduction is part of MaxCyte’s

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Fri, 11 Oct 2024 08:05:00 -0500

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.